(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Morgans healthcare and life sciences expert Iain Wilkie fills in for Scott Power this week, covering what the health movers ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...